PHVS
Pharvaris (PHVS)
$93
About Pharvaris (PHVS)
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.
Details
Daily high
$26.02
Daily low
$25.56
Price at open
$25.74
52 Week High
$29.80
52 Week Low
$11.51
Market cap
1.7B
Dividend yield
0.00%
Volume
57,093
Avg. volume
503,518
P/E ratio
-8.06
Pharvaris News
Details
Daily high
$26.02
Daily low
$25.56
Price at open
$25.74
52 Week High
$29.80
52 Week Low
$11.51
Market cap
1.7B
Dividend yield
0.00%
Volume
57,093
Avg. volume
503,518
P/E ratio
-8.06